Warning letters, 483s, Recalls, Import Alerts, Audit observations
Aurobindo arm, Eugia Pharma Specialities facility at Bhiwadi, Rajasthan was issued USFDA 483 with seven
USFDA inspection of Zydus Life sciences, Vadodara facility resulted in USFDA 483 with 10 observations.
In a Class 3 recall Teva initiated recall of one lot each of Nortrel and Nortrel
Sun Pharma initiated recall of several drugs manufactured at Dadra site (India) for cGMP deviation
Hospira Inc., a Pfizer company announced recall of several injectable products in US for potential
FDA had issued USFDA 483 in December 2022 to Novartis US site at Morris Plains,
USFDA issued a Warning letter to Intas, Matoda, Ahmedabad facility (FEI 3003157498) on 21 November
SCYNEXIS recalled 2 lots of Brexafemme (ibrexafungerp) tablets in U.S. due to potential cross contamination
SCYNEXIS issued the recall of 2 lots of BREXAFEMME (ibrexafungerp tablets) due to Potential for
Florida based VistaPharm LLC is recalling in US one lot of ulcer treatment drug Sucralfate
